PRISMS: the story of a pivotal clinical trial series in multiple sclerosis

Current Medical Research and Opinion
Bruce A Cohen, Victor M Rivera

Abstract

The PRISMS (Prevention of Relapses and disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) study was initiated in 1994, at which time there were few disease-modifying drugs for multiple sclerosis (MS). The PRISMS series of studies has since provided up to 8 years of clinical, magnetic resonance imaging (MRI), safety, and immunogenicity data on the use of subcutaneous (sc) interferon (IFN) beta-1a in patients with relapsing-remitting MS. This review is the first collation of all these data in one article, with a look ahead to the next generation of studies involving the new formulation of sc IFN beta-1a. Published efficacy, safety, and immunogenicity data, in terms of prospectively defined endpoints and later post hoc analyses, from years 1-8 of the PRISMS series are summarized and collated for the first time. Some of the studies of sc IFN beta-1a that evolved from the PRISMS studies are also discussed. In the 2-year, double-blind, randomized, placebo-controlled study, IFN beta-1a (22 or 44 mcg three times weekly [tiw]) was associated with significantly lower relapse rates, disability progression, and MRI burden of disease compared with placebo (p <or= 0.05). Subsequently, in the 2-year extension, patients pre...Continue Reading

References

Jan 1, 1986·Methods in Enzymology·Y Kawade
Aug 1, 1987·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·B G Weinshenker, G C Ebers
Oct 1, 1984·Neurology·J C SipeM B Oldstone
Mar 1, 1983·Annals of Neurology·C M PoserW W Tourtellotte
Feb 1, 1993·Brain : a Journal of Neurology·B Runmarker, O Andersen
Jan 1, 1995·Duodecim; lääketieteellinen aikakauskirja·M PaneliusJ Ruutiainen
May 30, 2001·Lancet·G ComiUNKNOWN Early Treatment of Multiple Sclerosis Study Group
Jun 13, 2001·Neurology·UNKNOWN Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-Beta-1a in MS (SPECTRIMS) Study Group
Jun 13, 2001·Neurology·D K LiUNKNOWN University of British Columbia MS/MRI Analysis Research Group. The SPECTRIMS Study Group
Jun 27, 2001·Neurology·UNKNOWN PRISMS Study Group and the University of British Columbia MS/MRI Analysis Group.
Jan 24, 2002·Neurology·D S GoodinUNKNOWN Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Pra
Nov 12, 2003·Neurology·Huub Schellekens
May 6, 2004·Multiple Sclerosis : Clinical and Laboratory Research·M ClanetUNKNOWN European IFNbeta-1a Dose-Comparison Study Investigators
May 19, 2004·Acta Neurologica Scandinavica·T FangerauUNKNOWN Multiple Sclerosis Study Group
Sep 9, 2004·Frontiers in Bioscience : a Journal and Virtual Library·Luca Durelli, Alessandra Ricci
May 11, 2005·Archives of Neurology·Steven R SchwidUNKNOWN University of British Columbia MS/MRI Research Group
Jul 13, 2005·Neurology·Gordon S FrancisUNKNOWN PRISMS Study Group
Jul 20, 2005·Journal of the Neurological Sciences·J OgerUNKNOWN PRISMS Study Group
Aug 2, 2005·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·R GoldUNKNOWN PRISMS Study Group
Nov 12, 2005·Annals of Neurology·Chris H PolmanJerry S Wolinsky
Dec 6, 2005·Multiple Sclerosis : Clinical and Laboratory Research·R A RudickA W Sandrock
Jun 13, 2006·Multiple Sclerosis : Clinical and Laboratory Research·C C FordUNKNOWN Copaxone Study Group
Jul 19, 2006·Journal of Rehabilitation Research and Development·Mitchell T WallinRobert Kane
Nov 23, 2006·Journal of Pharmaceutical and Biomedical Analysis·Amer Jaber, Matthew Baker
Feb 1, 2007·Multiple Sclerosis : Clinical and Laboratory Research·A C J W JanssensR Q Hintzen
Feb 14, 2007·Multiple Sclerosis : Clinical and Laboratory Research·M Korostil, A Feinstein
Jul 5, 2007·Journal of Clinical Nursing·Ann-Kristin IsakssonGerd Ahlström
Aug 30, 2008·Multiple Sclerosis : Clinical and Laboratory Research·G GiovannoniUNKNOWN Rebif New Formulation Study Group

❮ Previous
Next ❯

Citations

Jan 31, 2013·Pharmaceutical Research·Grzegorz KijankaVera Brinks
Jul 25, 2013·Pharmacology & Therapeutics·Danielle Murray, A Jon Stoessl
Jun 2, 2012·Multiple Sclerosis : Clinical and Laboratory Research·Devon S ConwayJeffrey A Cohen
Apr 7, 2018·Expert Opinion on Biological Therapy·Laura DumitrescuRadu Tanasescu
Oct 5, 2017·Expert Opinion on Drug Safety·Fabiana AuricchioConcetta Rafaniello
Dec 7, 2018·Journal of Neural Transmission·Marcel GebhardtUwe K Zettl
May 24, 2011·Journal of Obesity·Abdulwahab Naser Al-IsaNamal Wijesinghe
Jul 23, 2020·Der Nervenarzt·Marcel GebhardtUwe K Zettl
Apr 30, 2017·Therapeutic Advances in Neurological Disorders·Yvonne Benešová, Aleš Tvaroh
Jun 4, 2019·Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·S V KotovS B Magomedova
Jan 25, 2021·QJM : Monthly Journal of the Association of Physicians·L DumitrescuR Tanasescu

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.